U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of Medical Products and Tobacco
  5. Center for Drug Evaluation and Research | CDER
  6. Office of Drug Evaluation I - Division of Psychiatry Products
  1. Center for Drug Evaluation and Research | CDER

Office of Drug Evaluation I - Division of Psychiatry Products


The Office of New Drugs is undergoing a reorganization. This site may be updated in the near future. Please check back often. For more information, please visit Reorganization of the Office of New Drugs with Corresponding Changes to the Office of Translational Sciences and the Office of Pharmaceutical Quality.

The Division of Psychiatry Products (DPP) regulates and reviews Investigational New Drug (IND) applications and marketing applications for products for the treatment of psychiatric diseases and conditions, such as bipolar disorder, schizophrenia, schizoaffective disorder, major depressive disorder, attention deficit hyperactivity disorder, obsessive-compulsive disorder, panic attacks, posttraumatic stress disorder, generalized anxiety disorder, autism spectrum disorder, and insomnia. 

  • Director: Mitchell Mathis, M.D.
  • Deputy Director: Tiffany Farchione, M.D.
  • Deputy Director for Safety: Marc Stone, M.D.
  • Chief, Project Management Staff: Paul David, R.Ph.
  • Chief, Project Management Staff: Steve Hardeman, R.Ph.
  • Safety Regulatory Project Manager: Ermias Zerislassie, Pharm.D.
  • Management Specialist: Julia Elias

Contact Us:

Mailing Address: 

10903 New Hampshire Avenue, Silver Spring, MD 20993
Building 22, Suite 4200
Phone: (301) 796-2260
Fax: (301) 796-9841